Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma

被引：22

作者：

Kim, Kwang Min ^{[1
]}

Kim, Ho-Cheol ^{[1
,3
]}

Jeon, Kyung-Nyeo ^{[2
,3
]}

Kim, Hoon-Gu ^{[1
,3
,4
]}

Kang, Jung Hun ^{[1
,3
,4
]}

Hahm, Jong Ryeal ^{[1
,3
]}

Lee, Gyeong-Won ^{[1
,3
,4
]}

机构：

[1] Gyeongsang Natl Univ, Coll Med, Dept Internal Med, Div Hematol Oncol, Jinju 660702, South Korea

[2] Gyeongsang Natl Univ, Coll Med, Dept Diagnost Radiol, Jinju 660702, South Korea

[3] Gyeongsang Inst Hlth Sci, Jinju, South Korea

[4] Gyeongnam Reg Canc Ctr, Jinju, South Korea

来源：

YONSEI MEDICAL JOURNAL | 2008年 / 49卷 / 01期

关键词：

interstitial pneumonitis; rituximab; lymphoma;

D O I：

10.3349/ymj.2008.49.1.155

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 69-year-old male was diagnosed in February 2004 with stage IV extranodal marginal zone B cell lymphoma involving the mediastinal nodes, lung parenchyma and bone marrow with high LDH. Shortness of breath developed following the 5th course of Rituximab-CHOP chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Prednisolone). Bronchoscopy guided transbronchial lung biopsy revealed interstitial thickening and type II pneumocyte activation, compatible with interstitial pneumonitis. After treatment with prednisolone a complete resolution of the dyspnea was observed. The patient was well on routine follow-up at the outpatient clinic, with no progression of lymphoma or interstitial pneumonitis.

引用

收藏

页码：155 / 158

页数：4

相关论文

共 25 条

[1] Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease [J].

Ahmed, S ;

Kussick, SJ ;

Siddiqui, AK ;

Bhuiya, TA ;

Khan, A ;

Sarewitz, S ;

Steinberg, H ;

Sison, CP ;

Rai, KR .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (09) :1320-1326

[2] Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma [J].

Alexandrescu, DT ;

Dutcher, JP ;

O'Boyle, K ;

Albulak, M ;

Oiseth, S ;

Wiernik, PH .

LEUKEMIA & LYMPHOMA, 2004, 45 (11) :2321-2325

[3]

Algino KM, 1996, AM J CLIN PATHOL, V106, P78

[4] Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura [J].

Brændstrup, P ;

Bjerrum, OW ;

Nielsen, OJ ;

Jensen, BA ;

Clausen, NT ;

Hansen, PB ;

Andersen, I ;

Schmidt, K ;

Andersen, TM ;

Peterslund, NA ;

Birgens, HS ;

Plesner, T ;

Pedersen, BB ;

Hasselbalch, HC .

AMERICAN JOURNAL OF HEMATOLOGY, 2005, 78 (04) :275-280

[5]

Burton C, 2003, NEW ENGL J MED, V348, P2690

[6] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].

Byrd, JC ;

Peterson, BL ;

Morrison, VA ;

Park, K ;

Jacobson, R ;

Hoke, E ;

Vardiman, JW ;

Rai, K ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2003, 101 (01) :6-14

[7] Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance [J].

Byrd, JC ;

Waselenko, JK ;

Maneatis, TJ ;

Murphy, T ;

Ward, FT ;

Monahan, BP ;

Sipe, MA ;

Donegan, S ;

White, CA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :791-795

[8] State-of-the-art therapeutics: Diffuse large B-cell lymphoma [J].

Coiffier, B .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6387-6393

[9] Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type [J].

Conconi, A ;

Martinelli, G ;

Thiéblemont, C ;

Ferreri, AJM ;

Devizzi, L ;

Peccatori, F ;

Ponzoni, M ;

Pedrinis, E ;

Dell'Oro, S ;

Pruneri, G ;

Filipazzi, V ;

Dietrich, PY ;

Gianni, AM ;

Coiffier, B ;

Cavalli, F ;

Zucca, E .

BLOOD, 2003, 102 (08) :2741-2745

[10] First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: Phase II trial [J].

Hainsworth, JD ;

Litchy, S ;

Lamb, MR ;

Rodriguez, GI ;

Scroggin, C ;

Greco, FA .

CLINICAL LYMPHOMA, 2003, 4 (01) :36-42